Enveric Biosciences(US:ENVB)2026-03-27 21:27Financial Performance - Enveric Biosciences has not generated any revenues to date, operating as a pre-revenue biotech company[300]. - The net loss for 2025 was $8,771,987, compared to a net loss of $9,574,987 in 2024, reflecting an improvement of approximately 8%[1]. - Total operating expenses decreased to $8,774,448 in 2025 from $9,632,266 in 2024, a reduction of approximately 9%[1]. - Cash used in operating activities was $8,141,543 in 2025, compared to $7,726,139 in 2024, indicating an increase in cash outflows[5]. - The accumulated deficit reached $114,846,492 as of December 31, 2025, with further losses anticipated[7]. - Cash on hand at the end of 2025 was $4,677,491, which is insufficient to meet operating cash needs for the next 12 months[8]. Funding and Capital Raising - Enveric Biosciences raised approximately $10.5 million from the sales of common stock and warrants during the year ended December 31, 2025[300]. - The company issued 110,242 shares under the At the Market Offering Agreement for net cash proceeds of $1,636,799 as of December 31, 2025[286]. - A registered direct offering on January 27, 2026, resulted in gross proceeds of approximately $1.5 million from the sale of 328,802 shares at a price of $4.41 per share[287]. - Cash provided by financing activities increased to $10,579,507 in 2025 from $7,673,834 in 2024, representing a growth of approximately 38%[6]. - Management plans to raise additional working capital through public or private equity or debt financings to address liquidity concerns[9]. Research and Development - Research and development expenses are primarily focused on preclinical product candidates, with approximately 75% of staff dedicated to R&D activities[302]. - The EB-003 program is advancing through preclinical studies and is preparing for IND-enabling studies, including safety pharmacology and toxicology[284]. - The company aims to submit IND applications and NDAs to seek FDA approval for its product candidates[284]. - The EVM401 Series was unveiled to expand the pipeline with additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders[285]. - Research and development expenses decreased to $2,781,017 in 2025 from $2,841,272 in 2024, a decrease of $60,255, or approximately 2%[3]. Expenses and Cost Management - Stock-based compensation costs were approximately $0.8 million for the year ended December 31, 2025, down from $1.6 million in 2024[304]. - General and administrative expenses decreased by $660,932, or 10%, primarily due to reductions in legal fees, director fees, and stock compensation expenses[2]. - Depreciation and amortization expense decreased by $136,631, or approximately 40%, to $200,858 in 2025 due to full amortization of intangible assets[4]. Stock and Compliance - The company completed a reverse stock split of 1-for-12 on October 23, 2025, to regain compliance with Nasdaq listing requirements[294].